UE
VRTX icon

Unisphere Establishment’s Vertex Pharmaceuticals VRTX Stock Holding History

Unisphere Establishment’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,800
Closed -$9.67M – 69
2024
Q3 		$9.67M Sell
20,800
-1,200
-5% -$576K 0.09% 41
2024
Q2 		$10.3M Hold
22,000
– – 0.1% 42
2024
Q1 		$9.2M Hold
22,000
– – 0.09% 43
2023
Q4 		$8.95M Buy
+22,000
New +$8.13M 0.09% 48

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Unisphere Establishment's VRTX Position: Q4 2024 in Review

Unisphere Establishment sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 20,800 shares — an estimated $9.67M sold.

Unisphere Establishment first reported a position in VRTX in Q4 2023 and held it in 4 quarters. The position peaked at $10.3M in Q2 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Unisphere Establishment reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Unisphere Establishment sold 20,800 Vertex Pharmaceuticals shares in Q4 2024, an estimated $9.67M.
  • Unisphere Establishment first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Unisphere Establishment's Vertex Pharmaceuticals position peaked at $10.3M in Q2 2024.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Unisphere Establishment's 13F filing for Q4 2024, filed 14 Feb 2025.